TNF - tumor necrosis factor Gene

中文名称：肿瘤坏死因子

种属: Rattus norvegicus

同用名: Tnfa; RATTNF; TNF-alpha

基因 ID: 24835 | 基因类型: protein coding

关于 TNF

Primary_assembly 20: 3,622,011-3,624,629 forward strand.mRatBN7.2:CM026993.1

This gene has 2 transcripts (splice variants), 246 orthologues, 8 paralogues and is associated with 417 phenotypes. Biased expression in Thymus (RPKM 3.7), Spleen (RPKM 26.5) and 9 other tissues.

功能概要

该基因编码的蛋白可启动肿瘤坏死因子受体结合活性。参与多个过程，包括细胞通讯的正向调节；大分子代谢过程的正向调控；和神经元死亡的正调节。位于多个细胞成分中，包括质膜的外侧；细胞外空间；和神经细胞体。用于研究多种疾病，包括脑血管疾病（多发性）；肝病（多发性）；消化性食管炎;围产期坏死性小肠结肠炎；和脑室周围白质软化。多种疾病的生物标志物，包括脑部疾病（多种）；充血性心力衰竭（多发性）；炎症性肠病（多发性）；肺部疾病（多发）；和非酒精性脂肪性肝病（多种）。该基因的人类直系同源物与多种疾病有关，包括动脉疾病（多种）；自身免疫性疾病（多种）；眼病（多发）；肺部疾病（多发）；和皮肤病（多种）。与人类 TNF（肿瘤坏死因子）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables tumor necrosis factor receptor binding activity. Involved in several processes, including positive regulation of cell communication; positive regulation of macromolecule metabolic process; and positive regulation of neuron death. Located in several cellular components, including external side of plasma membrane; extracellular space; and neuronal cell body. Used to study several diseases, including cerebrovascular disease (multiple); liver disease (multiple); peptic esophagitis; perinatal necrotizing enterocolitis; and periventricular leukomalacia. Biomarker of several diseases, including brain disease (multiple); congestive heart failure (multiple); inflammatory bowel disease (multiple); lung disease (multiple); and non-alcoholic fatty liver disease (multiple). Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); autoimmune disease (multiple); eye disease (multiple); lung disease (multiple); and skin disease (multiple). Orthologous to human TNF (tumor necrosis factor). [provided by Alliance of Genome Resources, Apr 2022]

TNF 基因产物(1)

mRNA	Protein	Name
NM_012675.3	NP_036807.1	tumor necrosis factor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables tumor necrosis factor receptor binding	IDA IDA: 通过直接分析推断	12376316	RGD
enables tumor necrosis factor receptor binding	IPI IPI: 通过物理相互作用推断	20649583	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in calcium-mediated signaling	IDA IDA: 通过直接分析推断	12077131	RGD
involved in cell surface receptor signaling pathway via JAK-STAT	IDA IDA: 通过直接分析推断	29702085	RGD
involved in cellular response to amyloid-beta	IEP IEP: 通过表达模式推断	19004508	RGD
involved in cellular response to lipopolysaccharide	IEP IEP: 通过表达模式推断	10959811	RGD
involved in cellular response to lipopolysaccharide	IMP IMP: 通过突变表型推断	17964727	RGD
involved in cellular response to molecule of bacterial origin	IEP IEP: 通过表达模式推断	1580332	RGD
involved in cellular response to retinoic acid	IEP IEP: 通过表达模式推断	15602748	RGD
involved in cellular response to toxic substance	IEP IEP: 通过表达模式推断	9292703	RGD
involved in cellular response to type II interferon	IEP IEP: 通过表达模式推断	16525716	RGD
involved in circadian rhythm	IEP IEP: 通过表达模式推断	9483199	RGD
involved in detection of mechanical stimulus involved in sensory perception of pain	IMP IMP: 通过突变表型推断	16675114	RGD
involved in leukocyte migration involved in inflammatory response	IEP IEP: 通过表达模式推断	27939985	RGD
involved in liver regeneration	IEP IEP: 通过表达模式推断	9178702	RGD
involved in negative regulation of D-glucose import	IDA IDA: 通过直接分析推断	14764603	RGD
involved in negative regulation of L-glutamate import across plasma membrane	IDA IDA: 通过直接分析推断	15713255	RGD
involved in negative regulation of apoptotic process	IDA IDA: 通过直接分析推断	9395232	RGD
involved in negative regulation of bile acid secretion	IDA IDA: 通过直接分析推断	12563244	RGD
involved in negative regulation of cell population proliferation	IDA IDA: 通过直接分析推断	15476580	RGD
involved in negative regulation of fat cell differentiation	IDA IDA: 通过直接分析推断	10757205	RGD
involved in negative regulation of heart rate	IMP IMP: 通过突变表型推断	7875478	RGD
involved in negative regulation of myelination	IMP IMP: 通过突变表型推断	23982745	RGD
involved in negative regulation of oxidative phosphorylation	IDA IDA: 通过直接分析推断	8903396	RGD
involved in negative regulation of systemic arterial blood pressure	IMP IMP: 通过突变表型推断	7875478	RGD
involved in positive regulation of DNA biosynthetic process	IDA IDA: 通过直接分析推断	9395232	RGD
involved in positive regulation of action potential	IDA IDA: 通过直接分析推断	12684490	RGD
involved in positive regulation of apoptotic process	IMP IMP: 通过突变表型推断	16269520	RGD
involved in positive regulation of canonical NF-kappaB signal transduction	IDA IDA: 通过直接分析推断	12729461	RGD
involved in positive regulation of canonical NF-kappaB signal transduction	IGI IGI: 通过遗传相互作用推断	12631113	RGD
involved in positive regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis	IMP IMP: 通过突变表型推断	12131680	RGD
involved in positive regulation of fractalkine production	IDA IDA: 通过直接分析推断	12729461	RGD
involved in positive regulation of gene expression	IDA IDA: 通过直接分析推断	25158758	RGD
involved in positive regulation of gene expression	IMP IMP: 通过突变表型推断	9111198	RGD
involved in positive regulation of hepatocyte proliferation	IDA IDA: 通过直接分析推断	17557910	RGD
involved in positive regulation of hepatocyte proliferation	IMP IMP: 通过突变表型推断	9111198	RGD
involved in positive regulation of interleukin-18 production	IMP IMP: 通过突变表型推断	16269520	RGD
acts upstream of or within positive regulation of interleukin-6 production	IDA IDA: 通过直接分析推断	29702085	RGD
involved in positive regulation of interleukin-6 production	IMP IMP: 通过突变表型推断	10454827	RGD
involved in positive regulation of mitotic nuclear division	IMP IMP: 通过突变表型推断	12713870	RGD
involved in positive regulation of neuron apoptotic process	IMP IMP: 通过突变表型推断	14999074	RGD
involved in positive regulation of neutrophil activation	IMP IMP: 通过突变表型推断	8283134	RGD
involved in positive regulation of nitric-oxide synthase activity	IMP IMP: 通过突变表型推断	9537427	RGD
involved in positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	IMP IMP: 通过突变表型推断	12729461	RGD
involved in positive regulation of protein localization to plasma membrane	IMP IMP: 通过突变表型推断	11910117	RGD
involved in positive regulation of protein transport	IDA IDA: 通过直接分析推断	12118012	RGD
involved in positive regulation of synaptic transmission	IMP IMP: 通过突变表型推断	11910117	RGD
involved in positive regulation of transcription by RNA polymerase II	IDA IDA: 通过直接分析推断	12729461	RGD
involved in positive regulation of transcription by RNA polymerase II	IMP IMP: 通过突变表型推断	9834372	RGD
involved in regulation of cell population proliferation	IDA IDA: 通过直接分析推断	10757205	RGD
involved in response to 3,3',5-triiodo-L-thyronine	IEP IEP: 通过表达模式推断	15019085	RGD
involved in response to Gram-negative bacterium	IEP IEP: 通过表达模式推断	9466473	RGD
involved in response to L-glutamate	IDA IDA: 通过直接分析推断	15713255	RGD
involved in response to activity	IEP IEP: 通过表达模式推断	20007518	RGD
involved in response to bacterium	IEP IEP: 通过表达模式推断	8769813	RGD
involved in response to ethanol	IEP IEP: 通过表达模式推断	23277536	RGD
involved in response to fructose	IEP IEP: 通过表达模式推断	12364855	RGD
involved in response to gold nanoparticle	IEP IEP: 通过表达模式推断	23150627	RGD
involved in response to hypoxia	IEP IEP: 通过表达模式推断	15197744	RGD
involved in response to isolation stress	IEP IEP: 通过表达模式推断	33411841	RGD
involved in response to lipopolysaccharide	IEP IEP: 通过表达模式推断	11096136	RGD
involved in response to lipopolysaccharide	IMP IMP: 通过突变表型推断	25158758	RGD
involved in response to macrophage colony-stimulating factor	IEP IEP: 通过表达模式推断	24882100	RGD
involved in response to mechanical stimulus	IEP IEP: 通过表达模式推断	11834488	RGD
involved in response to nutrient levels	IEP IEP: 通过表达模式推断	17904344	RGD
involved in response to organic cyclic compound	IEP IEP: 通过表达模式推断	27939985	RGD
involved in response to xenobiotic stimulus	IEP IEP: 通过表达模式推断	19925291	RGD
involved in skeletal muscle contraction	IEP IEP: 通过表达模式推断	20007518	RGD
involved in toll-like receptor 3 signaling pathway	IMP IMP: 通过突变表型推断	25158758	RGD
involved in tumor necrosis factor-mediated signaling pathway	IMP IMP: 通过突变表型推断	12729461	RGD
involved in vasodilation	IMP IMP: 通过突变表型推断	16284227	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in external side of plasma membrane	IDA IDA: 通过直接分析推断	12622907	RGD
is active in extracellular region	IDA IDA: 通过直接分析推断	25049354	RGD
located in extracellular region	IDA IDA: 通过直接分析推断	12364855	RGD
located in extracellular space	IDA IDA: 通过直接分析推断	16269520	RGD
located in neuronal cell body	IDA IDA: 通过直接分析推断	11412877	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

TNF 蛋白结构

TNF

0
100
200
235 a.a.

蛋白主名

其他名称

tumor necrosis factor

cachectin	tumor necrosis factor (TNF superfamily, member 2)
tumor necrosis factor ligand superfamily member 2

重组 TNF 蛋白

目录号	产品名	蛋白编号	纯度
HY-P7108	TNF-alpha/TNFSF2 Protein, Rat (P.pastoris)	P16599 (L80-L235)	≥95%
HY-P70697	TNF-alpha/TNFSF2 Protein, Rat	P16599 (L80-L235)	≥95%

相关产品

Approval

生物活性分子 (19)

目录号	产品名	作用方式	纯度	是否罕见病
HY-12085	Apremilast		99.91%	是
HY-103399	Trovafloxacin mesylate	Inhibitor	99.56%	否
HY-N0281	Daphnetin		99.86%	否
HY-B1077	Penfluridol		99.93%	否
HY-13682	Mifamurtide		≥99.0%	否
HY-A0170	Trovafloxacin	Inhibitor	98.99%	否
HY-B1201	Tiratricol	Inhibitor	99.60%	是
HY-N0066	Eucalyptol	Inhibitor	≥98.0%	否
HY-30235A	Benzydamine hydrochloride	Inhibitor	98.22%	否
HY-B0164	Mizolastine	Antagonist	99.82%	否
HY-B0446	Naphazoline hydrochloride		98.12%	否
HY-13682B	Mifamurtide sodium		98.19%	否
HY-B0513	Methylthiouracil	Inhibitor	≥98.0%	否
HY-111326A	Naphazoline nitrate		≥98.0%	否
HY-13682C	Mifamurtide TFA		≥98.0%	否
HY-B1615	Clenbuterol	Agonist	/	否
HY-111326	Naphazoline		/	否
HY-30235	Benzydamine	Inhibitor	/	否
HY-B0164A	Mizolastine dihydrochloride	Antagonist	/	否

抗体抑制剂 (6)

目录号	产品名	作用方式	纯度	是否罕见病
HY-P9970	Infliximab	Inhibitor	90.30%	否
HY-P9908	Adalimumab	Inhibitor	99.62%	否
HY-108847	Etanercept	Inhibitor	99.20%	否
HY-P9953	Certolizumab pegol	Inhibitor	99.30%	否
HY-P99111	Golimumab		99.71%	否
HY-P99796	Ozoralizumab	Inhibitor	99.80%	否

Clinical Phase

生物活性分子 (23)

目录号	产品名	作用方式	纯度	Phase
HY-N3021	D-chiro-Inositol	Inhibitor	≥98.0%	Phase 4
HY-N8277	Kdo2-Lipid A ammonium		99.00%	Phase 4
HY-114360AS1	Taurohyodeoxycholic acid-d4 sodium	Inhibitor	/	Phase 4
HY-11109	Resatorvid	Inhibitor	99.95%	Phase 3
HY-13743	Roquinimex	Inhibitor	99.69%	Phase 3
HY-13740	Resiquimod		99.95%	Phase 2
HY-16591	Birinapant		99.70%	Phase 2
HY-110133	JTE-607	Inhibitor	99.27%	Phase 2
HY-15509A	Semapimod tetrahydrochloride	Inhibitor	98.43%	Phase 2
HY-119307	Apratastat	Inhibitor	99.67%	Phase 2
HY-118250	GSK2245035		99.85%	Phase 2
HY-145726	ISIS 104838	Inhibitor	/	Phase 2
HY-105017	Evodenoson	Agonist	99.74%	Phase 2
HY-U00179	CDC801	Inhibitor	98.94%	Phase 2
HY-114766	Pumafentrine	Inhibitor	/	Phase 2
HY-10172	IMD-0354	Inhibitor	99.51%	Phase 1
HY-13518	Piceatannol		98.90%	Phase 1
HY-107390	AX-024	Inhibitor	99.29%	Phase 1
HY-19717	DCVC	Inhibitor	99.83%	Phase 1
HY-15507	VGX-1027	Inhibitor	99.76%	Phase 1
HY-N0803	Myrcene	Inhibitor	≥75.0%	Phase 1
HY-107390A	AX-024 hydrochloride	Inhibitor	99.75%	Phase 1
HY-N8691	2',6'-Dihydroxy-4'-methoxydihydrochalcone	Inhibitor	/	Phase 1

抗体抑制剂 (16)

目录号	产品名	作用方式	纯度	Phase
HY-P99252	Itolizumab		≥99.0%	Phase 3
HY-P990070	Zigakibart	Inhibitor	98.37%	Phase 3
HY-P99499	Cetrelimab		≥99.0%	Phase 3
HY-P99578	Tanfanercept	Inhibitor	/	Phase 3
HY-P99692	Lenercept	Inhibitor	/	Phase 3
HY-P99772	Onfekafusp alfa		/	Phase 3
HY-P99670	Iscalimab	Inhibitor	99.64%	Phase 2
HY-P99315	Ruplizumab	Inhibitor	99.84%	Phase 2
HY-P99810	Quisovalimab		97.78%	Phase 2
HY-P99940	Remtolumab	Inhibitor	99.24%	Phase 2
HY-P9983	Lintuzumab		98.09%	Phase 2
HY-P99704	Licaminlimab	Inhibitor	96.10%	Phase 2
HY-P99775	Placulumab	Inhibitor	/	Phase 2
HY-P99945	Revdofilimab	Activator	99.35%	Phase 1
HY-P99178	CTX-471		99.42%	Phase 1
HY-P99361	Enavatuzumab	Inhibitor	≥95.0%	Phase 1

Pre-clinical Phase

生物活性分子 (463)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-13453	BAY 11-7082		99.98%	否
HY-N0822	Shikonin	Inhibitor	99.80%	否
HY-15648B	GSK-J4		99.64%	否
HY-P0224	N-Formyl-Met-Leu-Phe	Inhibitor	99.36%	否
HY-108473	CU-CPT 4a	Inhibitor	99.34%	否
HY-103490	Takinib		98.92%	否
HY-110203	R-7050	Antagonist	98.55%	否
HY-12326A	c-di-AMP disodium	Agonist	99.71%	否
HY-P1860	TNF-α (31-45), human		99.77%	否
HY-138682	STING-IN-2	Inhibitor	99.71%	否
HY-123942	Diprovocim	Agonist	98.35%	否
HY-13812	QNZ	Inhibitor	99.50%	否
HY-133122	UCB-9260	Inhibitor	99.96%	否
HY-122882	HOIPIN-8		99.89%	否
HY-109804	CORM-401	Inhibitor	98.27%	否
HY-126360	Oxazolone		≥98.0%	否
HY-13229	BOC-D-FMK	Inhibitor	≥95.0%	否
HY-100339	GSK583	Inhibitor	98.74%	否
HY-N0633	Muscone	Inhibitor	≥98.0%	否
HY-N0029	Forsythoside B		99.99%	否
HY-N0297	Sinensetin	Inhibitor	99.87%	否
HY-15648F	GSK-J4 hydrochloride	Inhibitor	99.01%	否
HY-100211	TAPI-2	Inhibitor	99.46%	否
HY-134471	TNF-α-IN-2	Inhibitor	98.75%	否
HY-110353	CU-T12-9	Agonist	98.94%	否
HY-N0509	Astilbin		99.97%	否
HY-N6796	Manumycin A		99.27%	否
HY-N0194	Asiatic acid		99.40%	否
HY-111255	SPD304	Inhibitor	99.58%	否
HY-19744	T6167923	Inhibitor	99.40%	否
HY-N0472	Geraniin	Inhibitor	99.84%	否
HY-107737	1,2-DLPC	Activator	≥98.0%	否
HY-N0405	Orientin	Inhibitor	99.73%	否
HY-107427	PF-3644022	Inhibitor	99.65%	否
HY-N0722	Neochlorogenic acid	Inhibitor	99.77%	否
HY-147141	HS-276	Inhibitor	98.59%	否
HY-148141	JPE-1375	Antagonist	99.94%	否
HY-N0043	Ginsenoside Rd	Inhibitor	99.88%	否
HY-14622	Necrostatin 2	Inhibitor	99.92%	否
HY-19975	RN-1734	Antagonist	99.86%	否
HY-142618	TNF-α-IN-6	Inhibitor	99.58%	否
HY-125402	GSK-843		99.18%	否
HY-147045	UCB-5307	Inhibitor	97.09%	否
HY-N6607	Tryptanthrin		99.89%	否
HY-N0619	Mulberroside A	Inhibitor	99.86%	否
HY-103360	J-113863	Antagonist	≥99.0%	否
HY-15511	Tyrphostin A9	Inhibitor	99.87%	否
HY-101448	TMI-1		99.59%	否
HY-150725	ODN 1585	Inducer	/	否
HY-133807	Benpyrine	Inhibitor	99.74%	否
HY-N1949	Homoplantaginin	Inhibitor	99.90%	否
HY-N0042	Ginsenoside Rc		≥98.0%	否
HY-12700	RO5256390		98.75%	否
HY-110177	SP-100030	Inhibitor	99.86%	否
HY-N7637	Tubuloside B	Inhibitor	99.95%	否
HY-108642B	AMG-548 dihydrochloride	Inhibitor	99.91%	否
HY-101849	Fasentin		≥98.0%	否
HY-103435	Vialinin A	Inhibitor	99.89%	否
HY-32018	Cot inhibitor-2	Inhibitor	99.65%	否
HY-131249	MK2-IN-3	Inhibitor	99.58%	否
HY-156454	UCB-6876	Inhibitor	99.96%	否
HY-N0316	Mollugin		99.48%	否
HY-111255A	SPD304 dihydrochloride	Inhibitor	99.96%	否
HY-N0569	Madecassic acid	Inhibitor	99.79%	否
HY-N2350	Cynaropicrin	Inhibitor	99.79%	否
HY-N0604	Ginsenoside Rh1	Inhibitor	≥98.0%	否
HY-W010201	Citronellol		98.60%	否
HY-125527	Resolvin D1		99.60%	否
HY-160412	TNFα activity modulator 3	Inhibitor	98.30%	否
HY-P1832A	PTD-p65-P1 Peptide TFA		99.14%	否
HY-124750	NecroX-7	Inhibitor	99.69%	否
HY-B0392	(S)-(+)-Rolipram		99.77%	否
HY-130252	YQ128	Inhibitor	99.83%	否
HY-134911	HS-243	Inhibitor	99.88%	否
HY-118922	IW927	Antagonist	99.04%	否
HY-123984	LTβR-IN-1	Activator	99.79%	否
HY-12511	SKF-86002	Inhibitor	99.66%	否
HY-P1847A	IKKγ NBD Inhibitory Peptide TFA		98.20%	否
HY-128598	MD2-TLR4-IN-1	Inhibitor	99.62%	否
HY-104073	CAY10602	Activator	98.65%	否
HY-114360A	Taurohyodeoxycholic acid sodium	Inhibitor	99.60%	否
HY-N4288	4-Methylesculetin	Inhibitor	98.21%	否
HY-N7056	4'-Hydroxychalcone	Inhibitor	99.66%	否
HY-128686	KAG-308	Agonist	99.88%	否
HY-112275	TNF-α-IN-1	Inhibitor	99.42%	否
HY-113402A	Gamma-glutamylcysteine TFA		95.20%	否
HY-139066	Punicic acid		≥98.0%	否
HY-152956	STING agonist-23	Agonist	99.16%	否
HY-N2055	Kaempferol 3-O-sophoroside		99.84%	否
HY-N2086	Ethyl palmitate	Inhibitor	99.05%	否
HY-N9965	2'-Fucosyllactose	Inhibitor	99.95%	否
HY-12557	γ-Glutamylvaline		99.73%	否
HY-116626	SM-7368	Inhibitor	99.77%	否
HY-N0613	Sauchinone	Inhibitor	99.88%	否
HY-N6246	Asperulosidic Acid	Inhibitor	99.72%	否
HY-32015	Cot inhibitor-1	Inhibitor	98.45%	否
HY-N0041	Ginsenoside Rb3	Inhibitor	99.12%	否
HY-128348	PK68	Inhibitor	99.92%	否
HY-W082785A	L6H21		99.46%	否
HY-N1356	Reticuline	Inhibitor	98.91%	否
HY-N2110	Phellopterin		99.94%	否
HY-N9445	Lacto-N-neotetraose		99.71%	否
HY-113953	Z-Asp-CH2-DCB	Inhibitor	99.64%	否
HY-118694	TAPI-0	Inhibitor	98.01%	否
HY-131945	CU-115	Antagonist	99.55%	否
HY-155998	NF-κB-IN-11	Inhibitor	98.42%	否
HY-N0617	Sanggenon C		98.50%	否
HY-12326B	c-di-AMP diammonium	Agonist	99.36%	否
HY-124151	Adenosine-2'-monophosphate	Activator	99.91%	否
HY-132248	C5 Lenalidomide	Inhibitor	99.62%	否
HY-150725C	ODN 1585 sodium	Inducer	93.90%	否
HY-N3316	Martynoside	Antagonist	≥99.0%	否
HY-100735	C 87	Inhibitor	98.06%	否
HY-135674	SR-318	Inhibitor	99.89%	否
HY-19667A	BMS-561392 formate	Inhibitor	99.38%	否
HY-120823	PF-05381941	Inhibitor	99.73%	否
HY-162734	BRD5075	Inhibitor	98.08%	否
HY-N2252	Licarin A	Inhibitor	98.48%	否
HY-N6253	Pinoresinol	Inducer	98.35%	否
HY-102040	Hispidol	Inhibitor	98.70%	否
HY-N0358	1,4-Dicaffeoylquinic acid	Inhibitor	99.80%	否
HY-N0506	Rosarin		99.94%	否
HY-N1987	Cucurbitacin IIb	Inducer	99.74%	否
HY-N3807	Enniatin B1	Inhibitor	99.34%	否
HY-P2612A	WP9QY TFA	Antagonist	99.83%	否
HY-12326	c-di-AMP	Agonist	99.29%	否
HY-133807A	(Rac)-Benpyrine	Inhibitor	99.30%	否
HY-110077	API-1		99.62%	否
HY-N0907	Ginsenoside Rg6		99.13%	否
HY-N2855	Alphitolic acid		≥97.0%	否
HY-N3063	Pimaric acid		99.83%	否
HY-N4323	14-Deoxyandrographolide	Inhibitor	99.47%	否
HY-N6857	Armepavine	Inhibitor	99.53%	否
HY-101041	(E)-AG 556	Inhibitor	99.92%	否
HY-112389	p38 MAP Kinase Inhibitor III	Inhibitor	98.77%	否
HY-141582	Ceramide 3		≥98.0%	否
HY-N0857	Deoxyandrographolide	Activator	99.87%	否
HY-N0906	Ginsenoside Rk3	Inhibitor	98.85%	否
HY-N9315	Episappanol	Inhibitor	98.57%	否
HY-P1825A	TNF-α (10-36), human TFA		96.52%	否
HY-P3722A	Mca-PLAQAV-Dpa-RSSSR-NH2 TFA		99.21%	否
HY-13740S	Resiquimod-d5		99.84%	否
HY-147263	Dovramilast	Inhibitor	99.83%	否
HY-150612	(R)-STU104	Inhibitor	99.91%	否
HY-123194	SIRT2/6-IN-1	Inhibitor	98.44%	否
HY-129113	α-Chaconine	Inhibitor	99.04%	否
HY-145498	HDMAPP triammonium	Activator	≥90.0%	否
HY-145726A	ISIS 104838 sodium		93.70%	否
HY-148454	Necroptosis-IN-3	Inhibitor	99.77%	否
HY-150729	ODN 1982	Inhibitor	/	否
HY-N1940	β-Anhydroicaritin	Inhibitor	99.09%	否
HY-N4285	Negletein	Inhibitor	99.55%	否
HY-P3585	Epobis	Inhibitor	99.34%	否
HY-157325	RIPK2-IN-5	Inhibitor	99.73%	否
HY-131707	LEO 39652	Inhibitor	99.51%	否
HY-110246	Quin C1	Agonist	98.47%	否
HY-112456	IKK2-IN-4	Inhibitor	99.89%	否
HY-151966	TD1092		99.49%	否
HY-152959	STING agonist-26	Agonist	99.56%	否
HY-156025	HCAR2 agonist 1		/	否
HY-N2205	Esculentoside H	Inhibitor	98.73%	否
HY-N3595	Cleomiscosin A	Inhibitor	99.15%	否
HY-N6073	Soyasapogenol A	Inhibitor	99.06%	否
HY-N6927	Isoforskolin	Inhibitor	≥98.0%	否
HY-P1860A	TNF-α (31-45), human TFA		/	否
HY-P2320	IDR-1	Inhibitor	99.01%	否
HY-W013675	2-Methoxyhydroquinone	Pre-designed Sets	/	否
HY-150219A	ODN M326 sodium	Inhibitor	/	否
HY-100376	CPI-1189	Inhibitor	98.49%	否
HY-106359A	Delmitide acetate	Inhibitor	98.55%	是
HY-108623	Atizoram	Inhibitor	96.3%	否
HY-117082	UTL-5g	Inhibitor	99.92%	否
HY-118157	3,5,7-Trimethoxyflavone	Inhibitor	98.94%	否
HY-12085S	Apremilast-d5		98.63%	否
HY-122786	3-O-Methylviridicatin	Inhibitor	/	否
HY-123936	SR12343	Inhibitor	≥98.0%	否
HY-125527S	Resolvin D1-d5		99.2%	否
HY-129151	Ganoderic acid C1		≥95.0%	否
HY-133807B	(R)-Benpyrine		99.17%	否
HY-135808	BIZ 114	Inhibitor	≥98.0%	否
HY-147086	CAY10789		99.84%	否
HY-147506	NOD2 antagonist 1	Antagonist	99.57%	否
HY-147696	SMTIN-T140		99.58%	否
HY-151369	AV123	Inhibitor	99.60%	否
HY-151876	Glucocorticoid receptor modulator 1		99.79%	否
HY-153579	Anti-inflammatory agent 42	Inhibitor	≥98.0%	否
HY-160178	Glucocorticoid receptor agonist-3 Ala-Ala-Mal		99.72%	否
HY-160179	Glucocorticoid receptor agonist-4	Agonist	99.80%	否
HY-161016	TNF/IFN-γ-IN-1	Inhibitor	99.39%	否
HY-169004	CBT-295	Inhibitor	99.34%	否
HY-18754A	FR 167653	Inhibitor	99.87%	否
HY-N0569R	Madecassic acid (Standard)	Inhibitor	/	否
HY-N0619A	cis-Mulberroside A	Inhibitor	≥96.0%	否
HY-N0811	Anemarsaponin B	Inhibitor	/	否
HY-N8413	Chlojaponilactone B	Inhibitor	≥98.0%	否
HY-P1875A	TNF-α (46-65), human TFA		99.20%	否
HY-P2612	WP9QY	Antagonist	/	否
HY-P3149B	LEESGGGLVQPGGSMK acetate		99.01%	否
HY-P3203A	DSTYSLSSTLTLSK TFA		98.11%	否
HY-114531	Lomifylline		99.67%	否
HY-156060	NCI126224	Inhibitor	99.88%	否
HY-W013557	3-Hydroxyxanthone	Inhibitor	≥98.0%	否
HY-131340	LASSBio-1632	Inhibitor	/	否
HY-132195	RORγt inverse agonist 14	Inhibitor	/	否
HY-19667	BMS-561392	Inhibitor	/	否
HY-18862	PF-03715455	Inhibitor	/	否
HY-100211A	(R)-TAPI-2	Control	/	否
HY-100702	SH-5		/	否
HY-101961	Tyrphostin AG 1288	Inhibitor	98.68%	否
HY-106359	Delmitide	Inhibitor	/	否
HY-108162A	Ataquimast	Inhibitor	/	否
HY-108641	SKF-86002 dihydrochloride	Inhibitor	/	否
HY-108642A	AMG-548 hydrochloride	Inhibitor	/	否
HY-108953	(S)-Quinolactacine A	Inhibitor	/	否
HY-111317	SIRT1 activator 3	Activator	/	否
HY-114221	Org 48762-0	Inhibitor	99.99%	否
HY-114573	TNF-α-IN-19	Inhibitor	/	否
HY-114592	M199		/	否
HY-114981	SRTCX1002	Activator	/	否
HY-115351	GW-3333	Inhibitor	/	否
HY-115913	PDE4-IN-6	Inhibitor	/	否
HY-115976	COX-2-IN-10	Inhibitor	/	否
HY-117356A	MRS2693 ammonium		/	否
HY-118101	15-Deoxy-Δ12,14-prostaglandin A1		/	否
HY-118250A	GSK2245035 maleate		/	否
HY-120041	ND-2158	Inhibitor	/	否
HY-120600	Sibiriline	Inhibitor	/	否
HY-121401	Myrtenal		/	否
HY-121996	Prostaglandin E2 Ethanolamide		/	否
HY-122292	Celastramycin A	Inhibitor	/	否
HY-122521	Sootepin D	Inhibitor	/	否
HY-123542	ONO-3403		/	否
HY-123736	Ro 32-7315	Inhibitor	/	否
HY-124003	Phytomonic acid		/	否
HY-124388	PDE4-IN-20		/	否
HY-124954	MN-25	Agonist	/	否
HY-126026	NF-κB-IN-17	Inhibitor	/	否
HY-126414	Methylenedihydrotanshinquinone		/	否
HY-128423AS	Tylvalosin-d9		/	否
HY-134950	(E)-C-HDMAPP ammonium	Activator	/	否
HY-136010	RIP2 Kinase Inhibitor 4	Inhibitor	/	否
HY-142069	KB-R7785	Inhibitor	/	否
HY-142958	NF-κB-IN-2		/	否
HY-14305	BMS-582949		/	否
HY-143410	Anti-inflammatory agent 16	Inhibitor	/	否
HY-144368	CO delivery molecule 1		/	否
HY-144727	Anti-inflammatory agent 11	Inhibitor	/	否
HY-144737	Anti-inflammatory agent 15	Inhibitor	/	否
HY-145492	Δ7(Z)-C14-HSL		/	否
HY-146419	Anti-inflammatory agent 20	Inhibitor	/	否
HY-146435	Anti-inflammatory agent 22	Inhibitor	/	否
HY-146483	Anti-Aβ agent 1A	Inhibitor	/	否
HY-146547	Anti-inflammatory agent 17	Inhibitor	/	否
HY-146723	IKKβ-IN-1	Inhibitor	/	否
HY-146765	AMS-17	Inhibitor	/	否
HY-147078	EJMC-1	Inhibitor	99.69%	否
HY-147697	LSD1-IN-21	Inhibitor	/	否
HY-147712	PKC-IN-4	Inhibitor	/	否
HY-147924	Keap1-Nrf2-IN-11	Inhibitor	/	否
HY-147950	PDE4-IN-10	Inhibitor	/	否
HY-148606	STING modulator-3	Inhibitor	/	否
HY-148908	TNF-α-IN-8		/	否
HY-149331	TNF-α-IN-11	Inhibitor	/	否
HY-149485	JNK2-IN-1	Inhibitor	/	否
HY-149816	Anti-inflammatory agent 41	Inhibitor	/	否
HY-149984	MAO-B-IN-21	Inhibitor	/	否
HY-150219	ODN M326	Agonist	/	否
HY-150725A	Biotin-labeled ODN 1585 sodium		/	否
HY-150725B	FITC-labeled ODN 1585 sodium	Inducer	/	否
HY-151188	DHU-Se1	Inhibitor	/	否
HY-152213	BET-IN-13	Inhibitor	/	否
HY-152957	STING agonist-24	Agonist	/	否
HY-152958	STING agonist-25	Agonist	/	否
HY-152961	STING agonist-28	Agonist	/	否
HY-153329	TNF-α-IN-9	Inhibitor	/	否
HY-153330	TNF-α-IN-10	Inhibitor	/	否
HY-153952	Immuno modulator-1	Inhibitor	/	否
HY-154698	Homouridine		/	否
HY-155027	DPP-4-IN-8	Inhibitor	/	否
HY-15509	Semapimod	Inhibitor	/	否
HY-155179	ZMF-23	Inhibitor	/	否
HY-155199	PDE1-IN-5	Inhibitor	/	否
HY-155243	12R-LOX-IN-1	Inhibitor	/	否
HY-155405	Anti-inflammatory agent 64	Inhibitor	/	否
HY-155753	Anti-inflammatory agent 50	Inhibitor	/	否
HY-155759	HMGB1-IN-2	Inhibitor	/	否
HY-155820	Anti-inflammatory agent 54	Inhibitor	/	否
HY-155821	Anti-inflammatory agent 55	Inhibitor	/	否
HY-15616	BMS-470539	Agonist	/	否
HY-156297	β5i-IN-1	Inhibitor	/	否
HY-156367	RIPK1-IN-16	Inhibitor	/	否
HY-157456	RIPK1-IN-19	Inhibitor	≥98.0%	否
HY-157546	VEGFR-2-IN-40	Inhibitor	/	否
HY-157809	Anti-inflammatory agent 74	Inhibitor	/	否
HY-157992	LM-021	Inhibitor	/	否
HY-159100	PVP-037	Agonist	/	否
HY-159516	Sabialimon P	Inhibitor	/	否
HY-159614	PG-PS	Activator	/	否
HY-159669	Stercobilin hydrochloride (mixture of isomers)	Inhibitor	/	否
HY-159884	MG-T-19		/	否
HY-159891	Microtubule destabilizing agent-2		/	否
HY-160027	TNF-alpha-IN-1	Inhibitor	/	否
HY-160180	Glucocorticoid receptor agonist-4 Ala-Ala-Mal		/	否
HY-160231	ssRNA42 sodium	Activator	/	否
HY-160433	TNF-α-IN-12	Inhibitor	/	否
HY-160434	TNF-α-IN-13	Inhibitor	/	否
HY-160435	TNF-α-IN-14	Inhibitor	/	否
HY-160436	TNF-α-IN-15	Inhibitor	/	否
HY-160437	TNF-α-IN-16	Inhibitor	/	否
HY-161240	MAO-B-IN-30	Inhibitor	98.53%	否
HY-161381	PDE4-IN-15	Inhibitor	/	否
HY-161520	Glucocorticoid receptor/NF-κB modulator-1		/	否
HY-161620	DW18134	Inhibitor	/	否
HY-161629	TLR8 agonist 7	Agonist	/	否
HY-161630	TLR8 agonist 8	Agonist	/	否
HY-161631	TLR8 agonist 9	Agonist	/	否
HY-161674	Monoamine Oxidase B inhibitor 4	Inhibitor	/	否
HY-161757	Anti-inflammatory agent 86		/	否
HY-161833	HSP90-IN-31	Inhibitor	/	否
HY-161901	BC-1293	Inhibitor	/	否
HY-161936	Z21115	Inhibitor	/	否
HY-161991	Caspase-3 activator 4		/	否
HY-162097	RIPK1-IN-20	Inhibitor	/	否
HY-162116	TLR7 agonist 18	Agonist	/	否
HY-162316	NF-κB-IN-15	Inhibitor	/	否
HY-162599	Spirohypertone B	Inhibitor	/	否
HY-162600	CDK8-IN-15	Inhibitor	/	否
HY-162641	AF-45	Inhibitor	/	否
HY-162649	TIC10g	Inhibitor	/	否
HY-162797	PDE4-IN-18	Inhibitor	/	否
HY-162850	DOR agonist 2		/	否
HY-162861	3-Methyl-chuangxinmycin	Inhibitor	/	否
HY-162963	PPARδ agonist 11	Agonist	/	否
HY-163102	IA-14069		/	否
HY-163280	JGB-1-155	Activator	/	否
HY-163368	HDAC6-IN-34	Inhibitor	/	否
HY-163670	TLR7 agonist 21	Inhibitor	/	否
HY-163673	Glucocorticoid receptor modulator 4	Modulator	/	否
HY-163747	VEGFR-2-IN-47	Inhibitor	/	否
HY-163748	GSK-3β inhibitor 17	Inhibitor	/	否
HY-163755	GPER activator 1		/	否
HY-163777	Talaroterphenyl A	Inhibitor	/	否
HY-163998	TLR4-IN-1		/	否
HY-164102	TNF-α-IN-18	Inhibitor	/	否
HY-164893	ABBV-154	Inhibitor	/	否
HY-164894	ABBV-3373	Inhibitor	/	否
HY-167877	PS-166276	Inhibitor	/	否
HY-168130	TNF-α/IL-1β-IN-1	Inhibitor	/	否
HY-168340	COX-2/15-LOX-IN-6	Inhibitor	/	否
HY-168734	CB2 receptor agonist 9	Agonist	/	否
HY-169103	Neuroprotective agent 5	Inhibitor	/	否
HY-169402	PDE1-IN-9	Inhibitor	/	否
HY-169417	Euphjatrophane M	Inhibitor	/	否
HY-169731	RO27-3225 trifluoroacetate	Agonist	/	否
HY-18759	BMS-751324	Inhibitor	/	否
HY-19717S	DCVC-13C3,15N		/	否
HY-N0041R	Ginsenoside Rb3 (Standard)	Inhibitor	/	否
HY-N0043R	Ginsenoside Rd (Standard)	Inhibitor	/	否
HY-N0066S	Eucalyptol-d6	Inhibitor	/	否
HY-N0604R	Ginsenoside Rh1 (Standard)	Inhibitor	/	否
HY-N0803S	Myrcene-d6	Inhibitor	/	否
HY-N0976	1,11b-Dihydro-11b-hydroxymedicarpin		/	否
HY-N10009	Cudraflavone B		/	否
HY-N10047	7,8-Didehydrocimigenol	Inhibitor	/	否
HY-N10448	Sinulatumolin E	Inhibitor	/	否
HY-N10453	Sinulatumolin D		/	否
HY-N10454	Sinulatumolin C	Inhibitor	/	否
HY-N10835	Gnetumontanin B		/	否
HY-N11768	4-Methoxylonchocarpin	Inhibitor	/	否
HY-N11892	7-O-Methylaloesinol	Inhibitor	/	否
HY-N11996	Aloenin aglycone		/	否
HY-N12042	Taxamairin B	Inhibitor	/	否
HY-N12186	Sibiricine		/	否
HY-N12653	Exserohilone	Inhibitor	/	否
HY-N12743	Farobin A	Inhibitor	/	否
HY-N13114	8-Gingerdione		/	否
HY-N1326	Santamarine		/	否
HY-N3364	Lucidone	Inhibitor	/	否
HY-N3380	Linderaspirone A	Inhibitor	/	否
HY-N3421	Koaburaside	Inhibitor	/	否
HY-N3552	Catalposide	Inhibitor	≥98.0%	否
HY-N3625	Coronalolic acid	Inhibitor	/	否
HY-N4061	Hedycoronen A	Inhibitor	/	否
HY-N4275	Oleaside A		/	否
HY-N5054	(R)-5,7-Dimethoxyflavanone	Inhibitor	≥99.0%	否
HY-N6969A	Dicentrine hydrochloride	Antagonist	/	否
HY-N7699A	D-Trimannuronic acid	Activator	/	否
HY-N8371	Shizukaol B	Inhibitor	/	否
HY-N8593	Undecane	Inhibitor	≥98.0%	否
HY-N8593S	Undecane-d24		/	否
HY-N8816	Stipuleanoside R2		/	否
HY-N8936	Narchinol B		/	否
HY-N9000	Loganic acid 6′-O-β-D-glucoside		/	否
HY-N9587	Tricin 7-O-β-D-glucopyranoside	Inducer	/	否
HY-N9699	8α-Hydroxyhirsutinolide	Inhibitor	/	否
HY-N9867	Gnetifolin E	Inhibitor	/	否
HY-P10241	Ac-LEHD-CHO	Inhibitor	/	否
HY-P10350	PapRIV	Agonist	/	否
HY-P10354	SPA4		/	否
HY-P10693	CZEN-002	Inhibitor	/	否
HY-P10770	P-ESBP-DOX	Inhibitor	/	否
HY-P1832	PTD-p65-P1 Peptide		/	否
HY-P1847	IKKγ NBD Inhibitory Peptide		/	否
HY-P3149	LEESGGGLVQPGGSMK		/	否
HY-P3149A	LEESGGGLVQPGGSMK TFA		/	否
HY-P3722	Mca-PLAQAV-Dpa-RSSSR-NH2		/	否
HY-RS14784	TNF Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS14785	Tnf Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS14786	TNF Rat Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-W010201R	Citronellol (Standard)		/	否
HY-W014049	N'-Nitro-D-arginine	Inhibitor	/	否
HY-W1000105	Geranial	Inhibitor	/	否
HY-W104821	Rosolic acid	Activator	/	否
HY-101410A	SDMA (p-hydroxyazobenzene-p′-sulfonate)		/	否
HY-10320A	Doramapimod hydrochloride	Inhibitor	/	否
HY-108162	Ataquimast free base	Inhibitor	/	否
HY-110133A	JTE-607 free base	Inhibitor	/	否
HY-110343	DBM 1285 dihydrochloride	Inhibitor	/	否
HY-116426	IDT	Modulator	/	否
HY-117569	KF24345 free base	Inhibitor	/	否
HY-117622	ND-2110	Inhibitor	/	否
HY-118316	GSK223	Inhibitor	/	否
HY-118984	CRX-526	Antagonist	/	否
HY-119799	UK-500001	Inhibitor	/	否
HY-12085S1	Apremilast-d8		/	否
HY-12085S3	Apremilast-d3		/	否
HY-121200	Azadirone		/	否
HY-122566	SMU127		/	否
HY-12348	LEO 29102	Inhibitor	/	否
HY-123882	IRAK4-IN-29		/	否
HY-125980	LX-3	Inhibitor	/	否
HY-126211	KBH-A42	Inhibitor	/	否
HY-126758	Ludartin	Inhibitor	/	否
HY-130073	Amorfrutin A		/	否
HY-134070	2-O-Methyl PAF C-16	Activator	/	否
HY-137370	2-Hexynyl-5′-N-ethylcarboxamidoadenosine		/	否
HY-138063	Siegeskaurolic acid	Inhibitor	/	否
HY-141582S	Ceramide 3-d3		/	否
HY-156431	Anti-inflammatory agent 61	Inhibitor	/	否
HY-158650	10-OAHSA	Inhibitor	/	否
HY-162579	TLR7 agonist 22	Agonist	/	否
HY-163642	TNF-α agonistic 1		/	否
HY-163712	17-Epiestriol	Agonist	/	否
HY-16658C	Z-VA-DL-D-FMK	Inhibitor	/	否
HY-169118	EGR-1-IN-2	Inhibitor	/	否
HY-171034	PQA-18	Inhibitor	/	否
HY-20070	BMS-566394	Inhibitor	/	否
HY-N1125	Triptobenzene H	Inhibitor	/	否
HY-N1159	Teuclatriol	Inhibitor	/	否
HY-N11994	Aloeresin G	Inhibitor	/	否
HY-N12116	Maceneolignan A	Inhibitor	/	否
HY-N12905	Celastramycin A (isomer)	Inhibitor	/	否
HY-N13184	Giraldoid B	Inhibitor	/	否
HY-N8015S1	Octanal-d2	Inhibitor	/	否
HY-N9541	Chaetoglobosin Vb		/	否
HY-W015879S	2-Heptanol-d5	Inhibitor	/	否
HY-W030338	aPKC-IN-2		/	否
HY-W071581	Glucocorticoid receptor activator 1	Activator	/	否
HY-W322573	(R)-Ketoprofen		/	否
HY-W505984	TPNA10168	Activator	/	否
HY-W753791	(±)-Perillaldehyde		/	否
HY-W923189	Neral	Inhibitor	/	否
HY-18754	FR 167653 free base	Inhibitor	/	否

抗体抑制剂 (7)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-P990008	Atrosab		98.00%	否
HY-P99148	Anti-Mouse TNF alpha Antibody (TN3-19.12)	Inhibitor	95.00%	否
HY-P9970A	Infliximab (Anti-TNF-α)	Inhibitor	99.00%	否
HY-P99782	Opinercept	Inhibitor	/	否
HY-P99565	Tengonermin	Inhibitor	/	否
HY-P99753	Nerelimomab	Inhibitor	/	否
HY-P9S0009	Adalimumab (Powder)	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	TNF	NCBI	NCBI:7124
Canis familiaris	TNF	NCBI	NCBI:403922
Macaca fascicularis	TNF	NCBI	NCBI:102139631
Mus musculus	TNF	NCBI	NCBI:21926
Susscrofa domestica	TNF	NCBI
Leporidae	TNF	NCBI
Macaca mulatta	TNF	NCBI	NCBI:715467

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.